NCT00961207

Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients

Study of Triple Blockade of the Renin Angiotensin Aldosterone System (RAAS) in Diabetic (Type 1&2) Proteinuric Patients With (ACE-, ARB, DRI)

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Cook County Health · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study Hypothesis: Reduction in albuminuria has been shown to decrease progression of diabetic nephropathy. In diabetic nephropathy patients treated with maximal antihypertensive doses with dual RAAS blockade (total daily dose valsartan 320 mg and either enalapril 40 mg or benazepril 40 mg daily, or losartan 100mg), persistent albuminuria reflects further additional RAAS activation. Microvascular renal disease due to increased RAAS activation may be more effectively treated with triple blockade by the addition of a direct renin inhibitor (DRI) Aliskiren.

Conditions

• Microalbuminuria
• Macroalbuminuric Diabetic Nephropathy
• Diabetes
• Proteinuria
• Albuminuria

Interventions

Type	Name	Description
DRUG	Aliskiren	Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
DRUG	Aliskiren	Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.

Timeline

• Start date: 2009-08-01
• Primary completion: 2012-07-01
• Completion: 2012-09-01
• First posted: 2009-08-18
• Last updated: 2013-10-28

Locations

1 site across 1 country: United States